AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELI LILLY & Co Director's Dealing 2026

Jan 6, 2026

29745_dirs_2026-01-06_397d3d8e-972d-48e0-a535-74c30736fa2e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2025-12-31

Reporting Person: Ho Carole (EVP & Pres, Lilly Neuroscience)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Unit	$		Common Stock (2741.306)		Direct

Footnotes

F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028.

F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.